1.
Hosier GW, Touma NJ. Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. CUAJ [Internet]. 2017 May 9 [cited 2022 May 26];11(5):E237-9. Available from: https://cuaj.ca/index.php/journal/article/view/4316